Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Regulus Therapeutics, Inc. Announces Commencement Of Public Offering Of Common Stock

October 28, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 27, 2014 /PRNewswire/ –Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs,today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately…

PharmAbcine Announces Global Licensing Deal With Triphase Accelerator For VEGFR-2/TIE 2 Bi-Specific Antibody

October 28, 2014 – 5:00 am | Edit Post

DAEJEON, Korea, TORONTO & SAN DIEGO–(BUSINESS WIRE)–PharmAbcine, a private biotechnology company focused on the discovery and development of novel bi-specific antibodies, today announced a new global licensing deal with Triphase Accelerator Corporation for a fully human, bi-specific antibody targeting VEGFR-2/TIE 2. The agreement provides Triphase with global development and commercial rights, while…

Triphase Accelerator Announces Expanded Collaboration With Celgene

October 28, 2014 – 5:00 am | Edit Post

TORONTO & SAN DIEGO–(BUSINESS WIRE)–Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced an expansion of its strategic collaboration with Celgene Corporation. The supplemental agreement adds a Phase I development program that will explore combining an intravenous (IV) formulation of marizomib…

Thermo Fisher Scientific Launches Industry???s Only End-To-End, NGS Genotyping Solution For Expanded Microbial Analysis

October 28, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif.–(BUSINESS WIRE)–Scientists conducting microbial research now have access to the industrys first end-to-end next-generation sequencing genotyping solution that enables culture-free assessment of complex bacterial populations. Designed for microbiome and industrial bioproduction applications, the new Ion 16S Metagenomics Kit provides a streamlined method for identifying bacteria from…

Triphase Accelerator Accelerator Corporation Announces New Collaboration With Celgene

October 28, 2014 – 5:00 am | Edit Post

TORONTO & SAN DIEGO–(BUSINESS WIRE)–Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced a new strategic collaboration with Celgene Corporation. The new agreement provides Celgene with the option to acquire a novel bi-specific antibody that Triphase licensed from PharmAbcine. The bi-specific…

Synthetic Genomics, Inc. Appoints MBA As Chief Executive Officer

October 28, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 27, 2014 /PRNewswire/ –Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive…

Synthetic Genomics, Inc. Appoints <b>Oliver Fetzer, Ph.D.</b>, MBA As Chief Executive Officer

October 28, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 27, 2014 /PRNewswire/ –Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive…

Neurocrine Biosciences, Inc. Announces Conference Call And Webcast To Report Third Quarter 2014 Financial Results

October 28, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 27, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2014 financial results after the Nasdaq market closes on Monday, November 3, 2014. Neurocrine will then host alive conference call and…

Receptos: good results for ulcerative colitis drug

October 27, 2014 – 5:43 pm | Edit Post

Receptos said a Phase 2 trial of its ulcerative colitis drug met its goals.

Synthetic Genomics names new CEO

October 27, 2014 – 5:16 pm | Edit Post

Synthetic Genomics has named a new CEO, Oliver Fetzer. Venter remains active with company.